Autopsy report · NCT04042051

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

“Accrual rate to date was too low to finish the trial in a reasonable timeframe”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Cancer Trials Ireland

Sponsor type

University, hospital or other

Conditions

HER2-positive Breast Cancer; Metastatic Breast Cancer; Locally Advanced Breast Cancer; Unresectable Breast Cancer

Interventions

Copanlisib; Trastuzumab emtansine

Participants

2

Sites

3

Countries

Ireland, Spain

Trials that died the same way

• Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
  “The trial closed early due to slow accrual.” (77% match in meaning)
• Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
  “The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve the target sample size within a reasonable timeframe. Consequently, a business decision has been made to discontinue funding for the trial.” (68% match in meaning)
• TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
  “The Sponsor had decided to terminate this clinical trial due to an insufficient rate of accrual of patients.” (67% match in meaning)
• Pre-operative Zoledronate in Triple Negative Breast Cancer
  “The study stopped prematurely due to the low accrual rate” (67% match in meaning)
• Analgesic Ear Drops for Children With Acute Otitis Media
  “Trial accrual problems” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.